

REMARKS

In said Office Action, an election requirement was raised to pending claims 1-74. The claims were placed in 6 groups: group I (claims 1-23, 39-40 and 56-59) drawn to a GDNF protein; group II (claims 24-25) drawn to a biochemical purification method; group III (claims 26-36 and 42-55) drawn to DNA encoding GDNF, host cells and a recombinant method of production; group IV (claims 37-38, 41 and 63-69) drawn to a method of treating a patient using GDNF; group V (claims 60-62) drawn to an antibody; and group VI (claims 70-74) drawn to an implantation device.

The Applicants hereby elect group III, claims 26-36 and 42-55, without traverse. It is believed that this election does not affect the inventorship of this application.

on 05-22-95
*HAD TOLD
HER TO
ELECT w/
TRAVERSE
JRC

Respectfully submitted,



Julie L. Bernard
Registration No. 36,450
Swanson & Bratschun, L.L.C.
8400 E. Prentice Ave., Suite 200
Englewood, CO 80111
(303) 793-3333

DATE: May 26, 1995

APPLICANT: Lin *et al.*

SERIAL NO.: 08/182,183

FOR: GLIAL DERIVED NEUROTROPHIC FACTOR

RECEIPT IS HEREBY ACKNOWLEDGED OF: Response to Office
Action

Swanson & Bratschun, L.L.C.
8400 E. Prentice Avenue, Suite 200
Englewood, CO 80111

5010 5010 1995

USV20

